Matthew Schnaderbeck

Matthew Schnaderbeck, Ph.D., serves as Sr. Director of CMC at Remix Therapeutics since April 2022, with prior experience as Director of Process and Discovery Process Chemistry at C4 Therapeutics, Inc. from March 2019 to April 2022. Matthew has also held the role of Drug Substance CMC Director and Project Consultant in the pharmaceutical industry between August 2018 and March 2019, and was a Senior Principal Scientist and Director at Eisai US from May 2000 to August 2018, focusing on CMC programs for natural product-based and small molecule APIs. Earlier, Matthew completed a post-doctorate at the University of Michigan under Prof. William Roush, specializing in organic synthesis from July 1998 to May 2000. Matthew earned a PhD in Chemistry from Stanford University and a BS in Chemistry from the University of Illinois Urbana-Champaign.